Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2972 studies found for:    Pulmonary Disease, Chronic Obstructive
Show Display Options
Rank Status Study
21 Unknown  Effect of Traditional Chinese Medicine on Outcomes in Patients With Mild/Moderate Chronic Obstructive Pulmonary Disease
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Traditional Chinese Medicine;   Drug: placebo chinese medicine
22 Unknown  Does Pulmonary Daoyin of China Give Additional Benefit Over Usual Therapy in Management of Stable Chronic Obstructive Pulmonary Disease?
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Other: Pulmonary daoyin therapy of China;   Other: usual care
23 Unknown  Cognitive Status in Chronic Obstructive Pulmonary Disease's Patients
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Other: Cognitive assessment
24 Completed Abdominal Functional Electrical Stimulation to Reduce Hyperinflation in Chronic Obstructive Pulmonary Disease Patients
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Device: Abdominal Stimulation - low / early;   Device: Abdominal stimulation - low/late;   Device: Abdominal Stimulation - low/full;   Device: Abdominal stimulation - med/early;   Device: Abdominal stimulation - med/late;   Device: Abdominal Stimulation - med/full;   Device: Abdominal Stimulation - high/early;   Device: Abdominal Stimulation - high/late;   Device: Abdominal Stimulation - high/full
25 Completed
Has Results
Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients
Conditions: Pulmonary Disease, Chronic Obstructive;   Major Depression
Interventions: Behavioral: Treatment Adherence Intervention;   Behavioral: Enhanced Care
26 Completed ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Salmeterol;   Drug: Fluticasone Propionate/Salmeterol Combination Product
27 Active, not recruiting A Study to Evaluate the Anti-inflammatory Effects of Solithromycin in Chronic Obstructive Pulmonary Disease
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Solithromycin;   Drug: Placebo
28 Completed
Has Results
Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: fluticasone/salmeterol combination (FSC) 250/50mcg;   Drug: tiotropium;   Drug: ipratropium bromide alone or in fixed dose combination with albuterol
29 Enrolling by invitation China Chronic Obstructive Pulmonary Disease Registration Research
Condition: Pulmonary Disease, Chronic Obstructive
Intervention:
30 Completed Short-term Telehealth Follow up After Hospital Discharge for Chronic Obstructive Pulmonary Disease Exacerbation
Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Procedure: Telemonitoring
31 Completed
Has Results
A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF/GW642444 Inhalation Powder;   Drug: FF Inhalation Powder;   Drug: GW642444 Inhalation Powder;   Drug: Placebo
32 Completed
Has Results
Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF Inhalation Powder;   Drug: FF/GW642444 Inhalation Powder;   Drug: GW642444 Inhalation Powder;   Drug: Placebo
33 Completed A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Conditions: Pulmonary Disease, Chronic Obstructive;   Chronic Obstructive Airway Disease
Interventions: Drug: GW856553;   Drug: Placebo;   Drug: Seretide
34 Completed
Has Results
Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: TIO;   Drug: TIO+FSC
35 Completed Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804;   Drug: Placebo
36 Completed Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways Disease
Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Drug: ATROVENT® inhalets
37 Completed Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease
Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Drug: Atrovent®
38 Completed Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease
Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Drug: Atrovent® Inhaletten
39 Completed Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Drug: Berodual® Respimat® solution for inhalation
40 Completed Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Drug: Berodual® Respimat® solution for inhalation

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.